We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A court decision that said Abbott Laboratories did not intentionally infringe on a patented hepatitis C virus technology should be reversed, multiplying damages against the company, according to an appeal filed by patent holder Innogenetics.
Multiple patent infringement lawsuits filed in federal court by Teva Pharmaceutical against competitors gearing up to market their own generic versions of Zoloft could jeopardize their efforts, legal sources say.
The U.S. Court of Appeals for the Federal Circuit brushed off an eleventh-hour request by Apotex asking it to reverse a decision it made last month upholding a block on sales of generic Plavix.
A federal court has upheld a preliminary injunction preventing Watson subsidiary Andrx Pharmaceuticals from marketing clarithromycin, a generic version of Abbott Laboratories’ extended-release antibiotic Biaxin XL.
A federal court invalidated one of two patents challenged by Sun Pharmaceuticals to market amifostine, a generic version of MedImmune Oncology’s dry mouth treatment drug, Ethyol.
A company’s right to challenge a patent that it is licensed to use is not restricted by the licensing agreement between it and the patent holder, the U.S. Supreme Court said in a Jan. 9 ruling.
A panel of drug industry representatives presented their views on the effects of reverse payment deals before federal lawmakers at a Senate hearing called to consider proposed legislation that could stop the practice of paying generic drug companies to limit market competition.
A federal district court has ordered Abbott Laboratories to immediately stop selling its diagnostic testing products developed with patented hepatitis C virus technology owned by biotech firm Innogenetics.
A federal court last week upheld one of two patents challenged by Sun Pharmaceutical Industries to market amifostine, a generic version of MedImmune Oncology’s dry mouth treatment drug, Ethyol.
The Supreme Court’s recent ruling upholding the right of a patent licensee to sue the patent holder may ease market entry for generic drug manufacturers who rely on abbreviated new drug applications to challenge the enforceability and validity of brand drug patents.